aganirsen (GS 101) / Gene Signal - LARVOL DELTA

A Phase 1 Study of GS101 Injection (clinicaltrials.gov) - P1 | N=294 | Recruiting | Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Phase 1 Study of GS101 Injection to Dupixent® (clinicaltrials.gov) - P1 | N=294 | Not yet recruiting | Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Phase III Study of GS101 Injection to Dupixent® (clinicaltrials.gov) - P3 | N=572 | Not yet recruiting | Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd

New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Corneal Neovascularization: Pathogenesis, Current Insights and Future Strategies. (PubMed, Biology (Basel)) - "Emerging therapies involve steroid-sparing immunosuppressants (including cyclosporine and rapamycin), anti-fibrotic agents and advanced drug delivery systems, including ocular nanosystems and viral vectors, to enhance drug bioavailability...Gene-based approaches, such as Aganirsen (antisense oligonucleotides) and CRISPR/Cas9-mediated VEGF-A editing, have shown promise in preclinical studies for CoNV regression and remission...Case studies of CoNV highlight the need for multifaceted approaches tailored to patient demographics and underlying ocular diseases. Future research and clinical trials are essential to elucidate optimal therapeutic strategies and explore combination therapies to ensure better management, improved treatment outcomes, and long-term remission of this visually disabling condition."

Journal • Review • Herpes Simplex • Infectious Disease • Inflammation • Keratitis • Mood Disorders • Ocular Infections • Ocular Inflammation • Ophthalmology • Thermal Injury

Aganirsen as a Therapeutic Alternative for Modulating Corneal Neovascularization: A Real-World Case Series Study. (PubMed, Clin Ophthalmol) - "This real-world study of the use of aganirsen months starting 1 week before graft surgery adds evidence of the clinical benefits of this agent in modulating neovascularization. Standardizing and extending the duration of treatment with aganirsen may further optimize the outcome of corneal transplantation."

Journal • Real-world evidence • Dermatology • Herpes Simplex • Immunology • Keratitis • Ocular Inflammation • Ophthalmology • Pruritus • Transplant Rejection • Transplantation • Uveitis • IRS1

GS-101. Opening General Session (ASM Microbe 2025) - "The session concludes with a featured scientific keynote presentation by Margie Lee, DVM, MS, Ph.D.. Don't miss this dynamic session with an update on ASM activities and a distinguished lineup of speakers showcasing the forefront of microbiology!"

HERVIN: variability in target selection and delineation for head and neck cancer radiotherapy in Europe (ESTRO 2025) - "Analysis of contours from 252 participants across 30 European countries (61% from academic institutions, 43% with >10 years of experience, treating an average of 40 head and neck patients annually) showed an interquartile range (IQR) of 261-325 cc (median 288 cc; GS 250 cc) for total contoured CTV and 99 to 113 cc for high-dose (HD) CTV (median 105 cc, GS 101 cc)... This largest performed study on interobserver variability in head and neck cancer radiotherapy revealed substantial variations in target selection and delineation among European oncologists. These findings emphasize the need for targeted training to standardize pratices. The observed variability also offers opportunities to explore its impact on treatment outcomes through large-scale real-world data studies."

Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor

Available Therapeutic Options for Corneal Neovascularization: A Review. (PubMed, Int J Mol Sci) - "Conventional treatments include anti-VEGF therapy and laser interventions, while emerging therapies such as immunosuppressive drugs (cyclosporine and rapamycin) have been explored. Losartan and decorin are potential antifibrotic agents that mitigate TGF-β-induced fibrosis...Aganirsen is efficacious in reducing the corneal neovascularization area without significant adverse effects. These multifaceted approaches underscore the corneal neovascularization management complexity and highlight ideas for enhancing therapeutic outcomes. Furthermore, the importance of combination therapies and the need for further research to develop specific inhibitors while considering their therapeutic efficacy and potential adverse effects are discussed."

Journal • Review • Fibrosis • Gene Therapies • Immunology • Ophthalmology • Transplantation • IL1R1 • TGFB1

Fine Needle Diathermy with and without Antisense Oligonucleotide Eye Drops Against Insulin Receptor Substrate-1 to Regress Corneal Neovascularization (ARVO 2024) - "Aganirsen combined with FND can regress not only hemangiogenesis but also lymphangiogenesis in the cornea in vivo. This suggests that Aganirsen combined with FND is a promising option to treat prevascularized corneas."

Ophthalmology • CD31 • IRS1 • LYVE1 • PECAM1

Electrophysiological characterization of voltage-dependent calcium-currents and TRPV4-currents in human pulmonary fibroblasts. (PubMed) - Am J Physiol Lung Cell Mol Physiol - "The voltage-dependent Ca2+-current is found to be 'L-type' in nature, as indicated by the voltage- and time-dependence of its activation, deactivation and inactivation properties, and by its pharmacology (sensitivity to replacement with barium; inhibition by nifedipine, verapamil or mibefradil). We also found that overnight treatment with TGFβ evoked a periodic current (inward at negative holding potentials, with reversal potential near 0 mV) which is sufficient to trigger the voltage-dependent Ca2+-currents and thereby account for the rhythmic Ca2+-oscillations which we have described previously in these cells."

Journal • Biosimilar • Fibrosis • Immunology • Systemic Sclerosis

Blockade of insulin receptor substrate-1 inhibits biological behavior of choroidal endothelial cells. (PubMed, Int J Ophthalmol) - "Blockade of IRS-1 can inhibit tube formation of HCECs through reducing cell proliferation and migration and promoting cell apoptosis."

Journal